Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outcome of extra-nodal follicular lymphoma affected by choice of induction chemoimmunotherapy and maintenance rituximab - real-world retrospective study.
Ng LCK, Ong SY, Huang X, Ghosh A, Nagarajan C, Goh YT, Chen Y, Lim FLWI, Tan MSY, Lee XH, Tan JY, Grigoropoulos NF, Yang VS, Hoe JTM, Chiang J, Chang EWY, Poon EYL, Tan YH, Somasundaram N, Tao M, Lim ST, Chan JY. Ng LCK, et al. Among authors: lim flwi. Leuk Lymphoma. 2024 Dec 28:1-7. doi: 10.1080/10428194.2024.2446615. Online ahead of print. Leuk Lymphoma. 2024. PMID: 39731562
Cabozantinib Plus Atezolizumab or Cabozantinib Alone in Patients With Advanced NSCLC Previously Treated With an Immune Checkpoint Inhibitor: Results From the Phase 1b COSMIC-021 Study.
Neal JW, Santoro A, Gonzalez-Cao M, Lim FL, Fang B, Gentzler RD, Goldschmidt J, Khrizman P, Proto C, Patel S, Puri S, Liu SV, Massarelli E, Williamson D, Schwickart M, Scheffold C, Andrianova S, Felip E. Neal JW, et al. Among authors: lim fl. JTO Clin Res Rep. 2024 Mar 20;5(10):100666. doi: 10.1016/j.jtocrr.2024.100666. eCollection 2024 Oct. JTO Clin Res Rep. 2024. PMID: 39318387 Free PMC article.
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON Trial.
Peters S, Cho BC, Luft AV, Alatorre-Alexander J, Geater SL, Laktionov K, Trukhin D, Kim SW, Ursol GM, Hussein M, Lim FL, Yang CT, Araujo LH, Saito H, Reinmuth N, Lowery C, Mann H, Stewart R, Jiang H, Garon EB, Mok T, Johnson ML. Peters S, et al. Among authors: lim fl. J Thorac Oncol. 2025 Jan;20(1):76-93. doi: 10.1016/j.jtho.2024.09.1381. Epub 2024 Sep 5. J Thorac Oncol. 2025. PMID: 39243945 Free article. Clinical Trial.
A high-density microfluidic bioreactor for the automated manufacturing of CAR T cells.
Sin WX, Jagannathan NS, Teo DBL, Kairi F, Fong SY, Tan JHL, Sandikin D, Cheung KW, Luah YH, Wu X, Raymond JJ, Lim FLWI, Lee YH, Seng MS, Soh SY, Chen Q, Ram RJ, Tucker-Kellogg L, Birnbaum ME. Sin WX, et al. Among authors: lim flwi. Nat Biomed Eng. 2024 Dec;8(12):1571-1591. doi: 10.1038/s41551-024-01219-1. Epub 2024 Jun 4. Nat Biomed Eng. 2024. PMID: 38834752
A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study.
Garon EB, Cho BC, Luft A, Alatorre-Alexander J, Geater SL, Trukhin D, Kim SW, Ursol G, Hussein M, Lim FL, Yang CT, Araujo LH, Saito H, Reinmuth N, Kohlmann M, Lowery C, Mann H, Peters S, Mok TS, Johnson ML. Garon EB, et al. Among authors: lim fl. Clin Lung Cancer. 2024 May;25(3):266-273.e5. doi: 10.1016/j.cllc.2024.03.003. Epub 2024 Mar 15. Clin Lung Cancer. 2024. PMID: 38584069 Free article. Clinical Trial. No abstract available.
69 results